Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Minerva Neurosciences (NERV) Accounts Payables (2016 - 2026)

Minerva Neurosciences filings provide 3 years of Accounts Payables readings, the most recent being $1.9 million for Q4 2021.

  • On a quarterly basis, Accounts Payables rose 86.14% to $1.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.9 million, a 86.14% increase, with the full-year FY2021 number at $1.9 million, up 86.14% from a year prior.
  • Accounts Payables hit $1.9 million in Q4 2021 for Minerva Neurosciences, up from $1.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.5 million in Q3 2020 to a low of $995614.0 in Q4 2020.
  • Median Accounts Payables over the past 3 years was $2.8 million (2021), compared with a mean of $2.9 million.
  • Biggest five-year swings in Accounts Payables: plummeted 75.95% in 2020 and later soared 86.14% in 2021.
  • Minerva Neurosciences' Accounts Payables stood at $4.1 million in 2019, then plummeted by 75.95% to $995614.0 in 2020, then soared by 86.14% to $1.9 million in 2021.
  • The last three reported values for Accounts Payables were $1.9 million (Q4 2021), $1.2 million (Q3 2021), and $2.8 million (Q2 2021) per Business Quant data.